We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
IPN.PA

Price
94.55
Stock movement up
+0.80 (0.85%)
Company name
Ipsen SA
Exchange
(PA
,
Currency
EUR
)
Sector
Healthcare >
Drug Manufacturers - Specialty & Generic
Market cap
7.82B
Ent value
9.84B
Price/Sales
1.57
Price/Book
1.93
Div yield
-
Div growth
-
Growth years
-
FCF payout
19.21%
Trailing P/E
8.92
Forward P/E
9.21
PEG
-
EPS growth
10.56%
1 year return
-11.05%
3 year return
-1.07%
5 year return
6.32%
10 year return
6.77%
Last updated: 2025-04-12

DIVIDENDS

IPN.PA does not pay dividends or no data was received

VALUATION

Valuation Ratios

Valuation Ratios data
Trailing P/E8.92
Price to OCF5.87
Price to FCF7.02
Price to EBITDA4.83
EV to EBITDA6.08

Valuation (Sales/Book Value)

Valuation (Sales/Book Value) data
Price to Sales1.57
Price to Book1.93
EV to Sales1.98

FINANCIALS

Per share

Per share data
Current share count82.71M
EPS (TTM)10.50
FCF per share (TTM)13.35

Income statement

Income statement data
Revenue (TTM)4.97B
Gross profit (TTM)4.08B
Operating income (TTM)1.11B
Net income (TTM)876.30M
EPS (TTM)10.50
EPS (1y forward)10.27

Margins

Margins data
Gross margin (TTM)82.12%
Operating margin (TTM)22.42%
Profit margin (TTM)17.65%

Balance Sheet

Please create a free account or log in to access this chart
Balance Sheet data
Cash485.40M
Net receivables719.20M
Total current assets1.90B
Goodwill685.30M
Intangible assets2.88B
Property, plant and equipment0.00
Total assets6.55B
Accounts payable857.60M
Short/Current long term debt490.20M
Total current liabilities1.67B
Total liabilities2.50B
Shareholder's equity4.05B
Net tangible assets0.00

Cash flow

Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)1.33B
Capital expenditures (TTM)175.50M
Free cash flow (TTM)1.11B
Dividends paid (TTM)214.00M

Financial returns

Please create a free account or log in to access this chart
Financial returns data
Return on Equity21.66%
Return on Assets13.38%
Return on Invested Capital20.96%
Cash Return on Invested Capital26.65%

STOCK INFORMATION

Stock chart

Stock price data
Open94.00
Daily high94.55
Daily low92.65
Daily Volume117K
All-time high153.15
1y analyst estimate129.50
Beta0.57
EPS (TTM)10.50
Dividend per share-
Ex-div date30 May 2024
Next earnings date28 May 2025

Downside potential

Downside potential data
IPN.PAS&P500
Current price drop from All-time high-38.26%-12.89%
Highest price drop-75.87%-56.47%
Date of highest drop18 Mar 20209 Mar 2009
Avg drop from high-25.62%-11.07%
Avg time to new high31 days12 days
Max time to new high1695 days1805 days
COMPANY DETAILS
IPN.PA (Ipsen SA) company logo
Marketcap
7.82B
Marketcap category
Mid-cap
Description
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.
Employees
5325
Website
https://www.ipsen.com
Investor relations
-
SEC filings
IPN.PA SEC filings
CEO
Country
France
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
UNDERSTAND THE BUSINESS
COMPANY NEWS
All newsPress releases
No items found
Disclaimer
Skyfall Technology OÜ assumes no responsibility or liability for any errors or omissions in the content of this site. The information contained in this site is provided on an “as is” basis with no guarantees of completeness, accuracy, usefulness or timeliness. Please also note, that any action you take upon the information provided on this website is strictly at your own risk. This website is intended to be used and must be used for informational purposes only and you should take independent financial advice from a professional and independently research and verify everything you see on the site.
Menu
HomePortfolio ManagementCompany ScreenerGreen InvestmentExchangesContact Us
Language
ENHUNOSVDAFIESDENLFRITPTPLCSSKROELTRRUAF
© 2024 Skyfall Technology OÜ All Rights Reserved